Pilot study of efficacy and safety of Rikkunshito for adverse events (nausea, emesis and anorexia) caused by chemotherapy (GD therapy) for high-grade soft tissue sarcomas.

Pilot study of efficacy and safety of Rikkunshito for adverse events (nausea, emesis and anorexia) caused by chemotherapy (GD therapy) for high-grade soft tissue sarcomas. - Pilot study of Rikkunshito for adverse events caused by chemotherapy (GD therapy).

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015120

Enrollment

Registered

2014-10-01

Start date

2014-10-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

High-grade soft tissue sarcomas

Interventions

Rikkunnshito 7.5g/day, 14days No Rikkunnshito

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with histologically-proved high-grade bone and soft tissue sarcoma Patients firstly applied modified MAID regimen Patients with healthy vital organs WBC >3000/mm3 and <20000/mm3 Neutrophils >1500/mm3 Hb >8.0g/dl Plat >8X104/mm3 Total Bil <2.0mg/dl ALT/AST <150IU/l Cr <1.5mg/dl Performance Status (ECOG) 0-2

Exclusion criteria

Exclusion criteria: 1. Patients with double cancer 2. Patients who took Kampo within 4 weeks 3. Patients with any other severe diseases 4. Pregnat patients 5. Other exclusionary comobidity

Design outcomes

Primary

Measure	Time frame
Nausea, emesis and anorexia (CTCAE ver4.0), EORTC QLQ-C30(version3)	—

Countries

Japan

Contacts

Public ContactTakahiro Goto

Tokyo Metropolitan Komagome Hospital Department of Musculoskeletal Oncology

goto-tky@cick.jp03-3823-2101

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026